Pfizer Inc. showcased its new oncology portfolio during a four-hour oncology innovation day on 29 February, just over two months after completing the acquisition of Seagen Inc. , a merger that significantly expands the company’s cancer drug portfolio and pipeline.
Key Takeaway
- Pfizer showcased its new oncology pipeline at an investor event after integrating Seagen.
- Pfizer did not provide sales targets for the oncology group but said the division will grow through 2030 despite the expected LOEs of its top-selling cancer drugs in 2027
Pfizer expects oncology, powered by the acquisition of Seagen, to be an important franchise over the next few years as the big pharma tries to grow despite declining COVID-19 revenues and the loss of
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
